Targovax ASA: third quarter 2020 results
Oslo, Norway, 5 November 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2020 results. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today (details below).RECENT HIGHLIGHTS · Announced that the ONCOS-102 and Imfinzi (durvalumab) trial successfully completed part 1 in colorectal cancer. The pre-defined disease control efficacy threshold in the colorectal cancer cohort was met and the part 2 has